Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer-Reference-Cited by-同舟云学术

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer

Published:2018-05 Issue:2 Volume:149 Page:275-282
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Oza Amit,Kaye Stanley,Van Tornout Jan,Sessa Cristiana,Gore Martin,Naumann R. Wendel,Hirte Hal,Colombo Nicoletta,Chen Jihong,Gorla Seema,Poondru Srinivasu,Singh Margaret,Steinberg Joyce,Yuen Geoff,Banerjee Susana

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference39 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J. Clin.,2015

2. Relapsed ovarian cancer: challenges and management strategies for a chronic disease;Armstrong;Oncologist,2002

3. Management of platinum-sensitive recurrent ovarian cancer;Pfisterer;Semin. Oncol.,2006

4. Weekly paclitaxel in the treatment of recurrent ovarian cancer;Baird;Nat. Rev. Clin. Oncol.,2010

5. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential;Banerjee;Clin. Cancer Res.,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer;Cells;2024-05-09

2. The efficacy of tyrosine kinase inhibitors combined with chemotherapy for recurrent ovarian cancer: a systematic review and network meta-analysis;Minerva Biotechnology and Biomolecular Research;2024-05

3. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma;JAMA Oncology;2023-05-01

4. Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs;Frontiers in Oncology;2023-04-11

5. Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer;PLOS ONE;2023-03-15